Bart C. De Jonghe, PhD, on Inflammation, Obesity and Cancer

New targeted therapies offer certain patients with non–small cell lung cancer more second-line treatment options.

In this episode of "The Vitals," Sarah Donahue, MPH, NP, AOCNP; Jamie Carroll, APRN, CNP, MSN; Theresa Wicklin Gillespie, PhD, MA, RN, FAAN; and Elizabeth Prechtel-Dunphy, DNP, RN, ANP-BC, AOCN, exchange clinical pearls for treating patients receiving antibody-drug conjugates.

Lindsey Zinck, PhD, RN, OCN, NEA-BC, and Melania Zisa, RN, BSN, OCN, discuss why it may be time to make the bell ringing ceremony a more inclusive celebration in cancer care.

Quizartinib plus standard intensive induction and consolidation therapy was associated with longer survival rates in patients with FLT3-ITD–positive acute myeloid leukemia.

Tetyana Furmanets, CRNP, MSN, discusses the tools she uses to help patients navigate myeloproliferative neoplasm symptom management.

Patients about to undergo Mohs microscopic surgery reported that they were more likely to request over-the-counter medications if they perceived their risk of opioid addiction to be high.